Oramed Pharma (ORMP)

$5.02 -0.01 (-0.20%)
Market Cap 209.23M
Revenue (ttm) 2.00M
Net Income (ttm) 64.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 4.11
Profit Margin 3,202.50%
Debt to Equity Ratio 0.00
Volume 242,800
Avg Vol 333,886
Day's Range N/A - N/A
Shares Out 41.60M
Stochastic %K 43%
Beta 1.22
Analysts Hold
Price Target $6.25

Company Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New Y...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 967 2633
Website: oramed.com
Address:
1185 Avenue of the Americas, Third Floor, New York, United States
ZacksSCR
ZacksSCR Aug. 28 at 3:14 PM
$ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness https://buff.ly/VNRsFY2
0 · Reply
Dutchholdem
Dutchholdem Aug. 27 at 11:45 AM
$ORMP rectification, Israel picked up again this number translates to 5.59 USD
0 · Reply
Dutchholdem
Dutchholdem Aug. 27 at 8:47 AM
$ORMP Israel trading at -5% at the moment. Top seems to be reached yesterday. Had a good run. Bearish next weeks, bullish long term.
0 · Reply
layLOW120
layLOW120 Aug. 26 at 5:56 PM
$ORMP where did they take it to this morning? Exactly 5.50..... We need to break 5.50, then game on.
1 · Reply
LivermoresGhost
LivermoresGhost Aug. 26 at 4:25 AM
$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!!!!!!!!!!!!!!!!!!!!!!!!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $NVCT $ORMP $BGDE $WW
0 · Reply
TimetheTrade
TimetheTrade Aug. 25 at 8:50 PM
$ORMP New 52-wk high! $5.25
0 · Reply
Dutchholdem
Dutchholdem Aug. 25 at 8:18 PM
$ORMP curious to see if/how TASE reacts to the action of today
1 · Reply
TimetheTrade
TimetheTrade Aug. 25 at 6:24 PM
$ORMP Almost got a new 52-week high @ $5.20. Needs to close above $5.
0 · Reply
layLOW120
layLOW120 Aug. 24 at 8:53 PM
$VBIO higher highs and higher lows.....See you all tomorrow $ORMP $IMUX $CURR $OBIO going next swingy swing
0 · Reply
Dutchholdem
Dutchholdem Aug. 21 at 3:16 PM
$DRTS added at 14.7 to make it a 5k shares total evenly split between normal and retirement account. 5k $ORMP shares as well with a 4-1 split
1 · Reply
Latest News on ORMP
Oramed Pharmaceuticals Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 22 days ago

Oramed Pharmaceuticals Quarterly report: Q2 2026

Oramed Pharmaceuticals Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Oramed Pharmaceuticals Proxy statement: Proxy filing

Oramed Pharmaceuticals Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Oramed Pharmaceuticals Proxy statement: Proxy filing

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Jun 25, 2026, 11:35 AM EDT - 2 months ago

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed to join Russell 2000 and 3000 indexes

2026-06-17T13:00:11.000Z - 2 months ago

Oramed to join Russell 2000 and 3000 indexes

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

Jun 17, 2026, 8:55 AM EDT - 2 months ago

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

Oramed Pharmaceuticals Quarterly report: Q1 2026

May 19, 2026, 8:00 AM EDT - 3 months ago

Oramed Pharmaceuticals Quarterly report: Q1 2026

Oramed Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Oramed Pharmaceuticals Annual report: Q4 2025

Lifeward closes strategic partnership agreement with Oramed

2026-03-25T20:45:17.000Z - 5 months ago

Lifeward closes strategic partnership agreement with Oramed

LFWD

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

LFWD

Oramed and Lifeward sign strategic transaction

2026-01-13T13:05:41.000Z - 8 months ago

Oramed and Lifeward sign strategic transaction

LFWD

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Jan 13, 2026, 8:00 AM EST - 8 months ago

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

LFWD

Oramed and Lifeward Announce Strategic Transaction

Jan 13, 2026, 7:58 AM EST - 8 months ago

Oramed and Lifeward Announce Strategic Transaction

LFWD

Oramed declares cash dividend payment of 25c per share

2026-01-07T14:00:51.000Z - 8 months ago

Oramed declares cash dividend payment of 25c per share

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Jan 7, 2026, 8:55 AM EST - 8 months ago

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Nov 17, 2025, 8:56 AM EST - 10 months ago

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Oramed declares dividend distribution of common stock purchase rights

2025-11-17T13:55:19.000Z - 10 months ago

Oramed declares dividend distribution of common stock purchase rights

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Nov 17, 2025, 8:50 AM EST - 10 months ago

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Oramed Pharmaceuticals Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Oramed Pharmaceuticals Quarterly report: Q3 2025

Oramed Pharmaceuticals Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Oramed Pharmaceuticals Earnings release: Q3 2025

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Oct 23, 2025, 8:55 AM EDT - 11 months ago

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Scilex completes first tranche of Oramed warrant repurchase

2025-10-01T13:05:56.000Z - 11 months ago

Scilex completes first tranche of Oramed warrant repurchase

SCLX

Oramed Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Quarterly report: Q2 2025

Oramed Pharmaceuticals Proxy statement: Proxy filing

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Proxy statement: Proxy filing

Oramed Pharmaceuticals Quarterly report: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Quarterly report: Q1 2025

Alpha Tau enters strategic marketing alliance with Oramed

2025-04-28T13:15:07.000Z - 1 year ago

Alpha Tau enters strategic marketing alliance with Oramed

DRTS

Alpha Tau enters strategic marketing alliance with Oramed

2025-04-28T13:12:39.000Z - 1 year ago

Alpha Tau enters strategic marketing alliance with Oramed

DRTS

Oramed announces $36.9M investment and collaboration with Alpha Tau

2025-04-28T13:05:43.000Z - 1 year ago

Oramed announces $36.9M investment and collaboration with Alpha Tau

DRTS

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

DRTS

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

DRTS

Oramed Pharmaceuticals Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Annual report: Q4 2024

Oramed Pharmaceuticals Issues Letter to Shareholders

Mar 4, 2025, 9:00 AM EST - 1 year ago

Oramed Pharmaceuticals Issues Letter to Shareholders

Oramed enters JV for insulin development and commercialization

2025-02-11T14:20:21.000Z - 1 year ago

Oramed enters JV for insulin development and commercialization

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Feb 11, 2025, 9:15 AM EST - 1 year ago

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Scilex announces early installment payment on senior secured promissory note

2024-12-16T14:15:51.000Z - 1 year ago

Scilex announces early installment payment on senior secured promissory note

SCLX

Oramed Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Oramed Pharmaceuticals Quarterly report: Q3 2024

Oramed announces restructuring of Scilex debt

2024-10-07T15:27:46.000Z - 2 years ago

Oramed announces restructuring of Scilex debt

SCLX

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oct 7, 2024, 10:00 AM EDT - 2 years ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

SCLX

Oramed Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Oramed Pharmaceuticals Quarterly report: Q2 2024

Oramed Letter to Shareholders

Jun 26, 2024, 9:05 AM EDT - 2 years ago

Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Jun 26, 2024, 9:00 AM EDT - 2 years ago

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Oramed Pharmaceuticals Proxy statement: Proxy filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Oramed Pharmaceuticals Proxy statement: Proxy filing

Oramed Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Oramed Pharmaceuticals Quarterly report: Q1 2024

Oramed Pharmaceuticals Annual report: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

Oramed Pharmaceuticals Annual report: Q4 2023

Oramed Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Oramed Pharmaceuticals Quarterly report: Q3 2023

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Sep 21, 2023, 6:11 PM EDT - 3 years ago

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Oramed Pharmaceuticals Quarterly report: Q2 2023

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Oramed Pharmaceuticals Quarterly report: Q2 2023

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Aug 2, 2023, 7:45 AM EDT - 3 years ago

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Oramed to Present at the 83rd American Diabetes Association Conference

Jun 20, 2023, 7:55 AM EDT - 3 years ago

Oramed to Present at the 83rd American Diabetes Association Conference

Oramed Pharmaceuticals Proxy statement: Proxy filing

May 31, 2023, 8:00 AM EDT - 3 years ago

Oramed Pharmaceuticals Proxy statement: Proxy filing

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 18, 2023, 7:55 AM EDT - 3 years ago

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

May 15, 2023, 9:05 AM EDT - 3 years ago

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed Pharmaceuticals Quarterly report: Q1 2023

May 11, 2023, 8:00 AM EDT - 3 years ago

Oramed Pharmaceuticals Quarterly report: Q1 2023

Oramed Pharmaceuticals Annual report: Q4 2022

Mar 6, 2023, 7:00 AM EST - 3 years ago

Oramed Pharmaceuticals Annual report: Q4 2022

Oramed Pharmaceuticals Issues Shareholder Update

Feb 9, 2023, 7:55 AM EST - 3 years ago

Oramed Pharmaceuticals Issues Shareholder Update

Oramed's oral insulin pill fails; stock is down 72%

Jan 12, 2023, 8:02 AM EST - 3 years ago

Oramed's oral insulin pill fails; stock is down 72%

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Jan 11, 2023, 8:00 PM EST - 3 years ago

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Jan 4, 2023, 7:55 AM EST - 3 years ago

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Nov 29, 2022, 8:40 AM EST - 4 years ago

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Nov 18, 2022, 4:11 AM EST - 4 years ago

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Nov 14, 2022, 7:55 AM EST - 4 years ago

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Oramed Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 4:30 PM EST - 4 years ago

Oramed Reports Third Quarter 2022 Financial Results

Oramed Pharmaceuticals Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

Oramed Pharmaceuticals Quarterly report: Q3 2022

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Nov 9, 2022, 8:40 AM EST - 4 years ago

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oct 7, 2022, 8:40 AM EDT - 4 years ago

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Sep 13, 2022, 8:40 AM EDT - 4 years ago

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 7:55 AM EDT - 4 years ago

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Oramed Pharmaceuticals Quarterly report: Q2 2022

Aug 10, 2022, 8:00 AM EDT - 4 years ago

Oramed Pharmaceuticals Quarterly report: Q2 2022

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Jul 26, 2022, 7:55 AM EDT - 4 years ago

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Jul 11, 2022, 7:55 AM EDT - 4 years ago

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Oramed Pharmaceuticals Proxy statement: Proxy filing

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Oramed Pharmaceuticals Proxy statement: Proxy filing

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Jun 1, 2022, 7:55 AM EDT - 4 years ago

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Oramed to Present at H.C. Wainwright Global Investment Conference

May 18, 2022, 7:55 AM EDT - 4 years ago

Oramed to Present at H.C. Wainwright Global Investment Conference

Oramed Pharmaceuticals Quarterly report: Q1 2022

May 12, 2022, 8:00 AM EDT - 4 years ago

Oramed Pharmaceuticals Quarterly report: Q1 2022

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

May 3, 2022, 8:10 AM EDT - 4 years ago

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Oramed Appoints Yadin Rozov to its Board of Directors

Apr 4, 2022, 8:25 AM EDT - 4 years ago

Oramed Appoints Yadin Rozov to its Board of Directors

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Mar 29, 2022, 8:25 AM EDT - 4 years ago

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Mar 22, 2022, 8:25 AM EDT - 4 years ago

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Oramed to Present at Barclays Global Healthcare Conference

Mar 10, 2022, 8:25 AM EST - 4 years ago

Oramed to Present at Barclays Global Healthcare Conference

Oramed Issues Annual Message to Shareholders

Jan 12, 2022, 8:45 AM EST - 5 years ago

Oramed Issues Annual Message to Shareholders

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

Jan 5, 2022, 7:30 AM EST - 5 years ago

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Dec 29, 2021, 9:15 AM EST - 5 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Dec 29, 2021, 6:14 AM EST - 5 years ago

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Dec 29, 2021, 6:00 AM EST - 5 years ago

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Dec 14, 2021, 8:00 AM EST - 5 years ago

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Oramed Pharmaceuticals Appoints Chief Legal Officer

Dec 8, 2021, 7:30 AM EST - 5 years ago

Oramed Pharmaceuticals Appoints Chief Legal Officer

Oramed to Join MSCI USA Small Cap Index

Nov 24, 2021, 8:40 AM EST - 5 years ago

Oramed to Join MSCI USA Small Cap Index

ZacksSCR
ZacksSCR Aug. 28 at 3:14 PM
$ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness https://buff.ly/VNRsFY2
0 · Reply
Dutchholdem
Dutchholdem Aug. 27 at 11:45 AM
$ORMP rectification, Israel picked up again this number translates to 5.59 USD
0 · Reply
Dutchholdem
Dutchholdem Aug. 27 at 8:47 AM
$ORMP Israel trading at -5% at the moment. Top seems to be reached yesterday. Had a good run. Bearish next weeks, bullish long term.
0 · Reply
layLOW120
layLOW120 Aug. 26 at 5:56 PM
$ORMP where did they take it to this morning? Exactly 5.50..... We need to break 5.50, then game on.
1 · Reply
LivermoresGhost
LivermoresGhost Aug. 26 at 4:25 AM
$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!!!!!!!!!!!!!!!!!!!!!!!!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $NVCT $ORMP $BGDE $WW
0 · Reply
TimetheTrade
TimetheTrade Aug. 25 at 8:50 PM
$ORMP New 52-wk high! $5.25
0 · Reply
Dutchholdem
Dutchholdem Aug. 25 at 8:18 PM
$ORMP curious to see if/how TASE reacts to the action of today
1 · Reply
TimetheTrade
TimetheTrade Aug. 25 at 6:24 PM
$ORMP Almost got a new 52-week high @ $5.20. Needs to close above $5.
0 · Reply
layLOW120
layLOW120 Aug. 24 at 8:53 PM
$VBIO higher highs and higher lows.....See you all tomorrow $ORMP $IMUX $CURR $OBIO going next swingy swing
0 · Reply
Dutchholdem
Dutchholdem Aug. 21 at 3:16 PM
$DRTS added at 14.7 to make it a 5k shares total evenly split between normal and retirement account. 5k $ORMP shares as well with a 4-1 split
1 · Reply
layLOW120
layLOW120 Aug. 20 at 6:01 PM
$ORMP this breaks 5 it becomes marginable and big boys are definitely loading..... Next legs 5.25 then 5.50 then game on to 7.50
3 · Reply
Dutchholdem
Dutchholdem Aug. 20 at 1:44 PM
$ORMP looks like we are at a profit taking point. I am just looking at drts value within ormp, therefore not selling below 5.5 ;)
0 · Reply
Dutchholdem
Dutchholdem Aug. 18 at 7:56 PM
$ORMP seems it has attracted some bigger buyer last 2 days. Current $DRTS position only of ORMP accounts for a shareprice of around 5.60-5.70 dollar shareprice for ORMP, currently just below 4.80. Add in other positions and it's still discounted.
0 · Reply
Dutchholdem
Dutchholdem Aug. 17 at 10:48 AM
$ORMP nice premarket bump today corresponding with TASE level which is at 4.73 dollar at the moment
0 · Reply
Dutchholdem
Dutchholdem Aug. 12 at 10:58 AM
$ORMP monster quarterly earnings of 1.84 dollar per share on a 4.25 dollar stock. Mostly thanks to $DRTS gains
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 11 at 5:20 PM
ORMP Q2 2026 Earnings Summary $ORMP https://stocktwits.com/news/earnings/ai summaries/ormp-q2-2026-earnings-summary/cZoNPPmRJXd
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 11 at 2:10 PM
$ORMP Q2 '26 Earnings Results & Recap Reported GAAP EPS of $1.90 up 493.75% YoY
0 · Reply
Dutchholdem
Dutchholdem Aug. 4 at 5:38 PM
$ORMP curious how earnings will be received on this one. Around 310 million in funds of which 210 million in $DRTS . All that with a market cap of 178 million dollar with the current shareprice of 4.35 which is quite a hefty discount on the funds managed
0 · Reply
CocoBoudin
CocoBoudin Jul. 14 at 5:59 PM
$NNDM bit of a wildcard idea…. Adopt an operating model like Oramed. As we see, they basically invest in distressed or targeted assets and then conduct off-exchange trades with their ‘partners’ such as Murch. They make money by shorting and long trading in stocks like $DRTS . They use the gains to fund development of medicines. Seems to be working for $ORMP Nano as best part of 500m to play with and two of our activists are very good at this model. Why Murch not proposing this?
0 · Reply
shimblum
shimblum Jul. 13 at 4:12 PM
$ORMP how many shares of $DRTS does Oramed have?
3 · Reply
CocoBoudin
CocoBoudin Jul. 1 at 2:59 AM
$NNDM it’s going to get exciting. Might get the ticker trending. Any short squeeze potential could be doubly exciting. Murch and $ORMP could get caught with their pants down if they have short sales to cover.
0 · Reply
focafoca99
focafoca99 Jun. 30 at 8:26 PM
$ORMP amends its bylaws and extends a payment extension with Scilex, covering $36.2M of note obligations.
0 · Reply